These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 28386057)

  • 1. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
    Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
    Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
    Isakov V; Paduta D; Viani RM; Enejosa JV; Pasechnikov V; Znoyko O; Ogurtsov P; Bogomolov PO; Maevskaya MV; Chen X; Shulman NS
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1073-1076. PubMed ID: 29762255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
    Dore GJ; Conway B; Luo Y; Janczewska E; Knysz B; Liu Y; Streinu-Cercel A; Caruntu FA; Curescu M; Skoien R; Ghesquiere W; Mazur W; Soza A; Fuster F; Greenbloom S; Motoc A; Arama V; Shaw D; Tornai I; Sasadeusz J; Dalgard O; Sullivan D; Liu X; Kapoor M; Campbell A; Podsadecki T
    J Hepatol; 2016 Jan; 64(1):19-28. PubMed ID: 26321288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
    Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
    J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
    Manuel Sousa J; Vergara M; Pulido F; Sánchez Antolín G; Hijona L; Carnicer F; Rincón D; Salmerón J; Mateos-Muñoz B; Jou A; Polo-Lorduy B; Rubín Á; Escarda A; Aguilar P; Aldámiz-Echevarría T; García-Buey L; Carrión JA; Hernández-Guerra M; Chimeno-Hernández S; Espinosa N; Morillas RM; Andrade RJ; Delgado M; Gallego A; Magaz M; Moreno-Planas JM; Estébanez Á; Rico M; Menéndez F; Sampedro B; Morano L; Izquierdo S; Zozaya JM; Rodríguez M; Morán-Sánchez S; Lorente S; Martín-Granizo I; Von-Wichmann MÁ; Delgado M; Manzanares A
    PLoS One; 2019; 14(11):e0225061. PubMed ID: 31714950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
    Sato K; Chayama K; Alves K; Toyoda H; Suzuki F; Kato K; Rodrigues L; Zhang X; Setze C; Pilot-Matias T; Burroughs M; Redman R; Kumada H
    Adv Ther; 2017 Jun; 34(6):1449-1465. PubMed ID: 28536999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
    Pessoa MG; Ramalho-Madruga JV; Alves K; Nunes EP; Cheinquer H; Brandão-Mello CE; Mendes-Correa MC; Ferraz ML; Ferreira PRA; Álvares-da-Silva MR; Coelho HS; Affonso-de-Araújo ES; Furtado J; Parana R; Silva G; Lari SA; Liu L; Tripathi R; Pilot-Matias T; Cohen DE; Shulman NS; Martinelli A
    Ann Hepatol; 2018 Oct; 17(6):959-968. PubMed ID: 30600291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
    Flisiak R; Janczewska E; Wawrzynowicz-Syczewska M; Jaroszewicz J; Zarębska-Michaluk D; Nazzal K; Bolewska B; Bialkowska J; Berak H; Fleischer-Stępniewska K; Tomasiewicz K; Karwowska K; Rostkowska K; Piekarska A; Tronina O; Madej G; Garlicki A; Lucejko M; Pisula A; Karpińska E; Kryczka W; Wiercińska-Drapało A; Mozer-Lisewska I; Jabłkowski M; Horban A; Knysz B; Tudrujek M; Halota W; Simon K
    Aliment Pharmacol Ther; 2016 Nov; 44(9):946-956. PubMed ID: 27611776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
    Yu ML; Chen YL; Huang CF; Lin KH; Yeh ML; Huang CI; Hsieh MH; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL
    J Formos Med Assoc; 2018 Jun; 117(6):518-526. PubMed ID: 28662883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
    Gheorghe L; Iacob S; Curescu M; Brisc C; Cijevschi C; Caruntu F; Stanciu C; Simionov I; Sporea I; Gheorghe C; Iacob R; Arama V; Sirli R; Trifan A
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):275-281. PubMed ID: 28922440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
    Deutsch L; Houri I; Ben-Ari Z; Shlomai A; Veitsman E; Cohen-Ezra O; Issachar A; Mor O; Gozlan Y; Bruck R; Menachem Y; Zelber-Sagi S; Katchman H; Shibolet O
    BMC Infect Dis; 2020 Apr; 20(1):264. PubMed ID: 32245397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
    Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
    Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
    Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
    J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
    Petta S; Marzioni M; Russo P; Aghemo A; Alberti A; Ascione A; Antinori A; Bruno R; Bruno S; Chirianni A; Gaeta GB; Giannini EG; Merli M; Messina V; Montilla S; Perno CF; Puoti M; Raimondo G; Rendina M; Silberstein FC; Villa E; Zignego AL; Pani L; Craxì A; ;
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):427-434. PubMed ID: 28497758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
    J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
    Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
    Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
    Rosenthal P; Narkewicz MR; Yao BB; Jolley CD; Lobritto SJ; Wen J; Molleston JP; Hsu EK; Jonas MM; Zha J; Liu L; Leung DH
    Adv Ther; 2020 Jul; 37(7):3299-3310. PubMed ID: 32451952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
    Shiffman ML; Rustgi V; Bennett M; Forns X; Asselah T; Planas Vila R; Liu L; Pedrosa M; Moller J; Reau N
    Am J Gastroenterol; 2016 Jun; 111(6):845-51. PubMed ID: 27045929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
    Khatri A; Mensing S; Podsadecki T; Awni W; Menon R; Dutta S
    Clin Drug Investig; 2016 Aug; 36(8):625-35. PubMed ID: 27153823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.